SEC Form 4 · accession 0000899243-17-006895
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel W Muehl
Officer — See Remarks
Period of report
Mar 8, 2017
Accepted (ET)
Mar 8, 2017 · 8:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2017 | M | 1,250 | — | A | 1,250 | D | |
| Common Stock | Mar 8, 2017 | F | 400 | $59.27 | D | 850 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F1 | — | Mar 8, 2017 | M | 1,250 | D | — | — | Common Stock | 1,250 | 1,250 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the right to receive one share of Common Stock.
- F2On March 1, 2016, the reporting person was granted 2,500 Restricted Stock Units, vesting in two equal annual installments beginning on the first anniversary of the grant date. The Issuer settled the Restricted Stock Units that vested on March 1, 2017 on March 8, 2017.
Remarks
Senior Vice President of Finance, Principal Financial Officer and Principal Accounting Officer